Health Medical

John J. Nava M.D.

Mailing Address : P.O. Box **0825 . San Antonio, Texas . 78283 0825

Cellular : 210-***-****

Email Address : ***********@*****.***

Licensure: H4572 Texas

Texas DPS Controlled Substances Registration

DEA Registration

Education:

Central Catholic Marianist High School 1971 1975

Trinity University 1975 1979

B.A. Biology

Baylor College of Medicine, Houston, Texas 1979 1980

M.D. 1981 1985

Texas Tech University Health Science Center, Lubbock, Texas 1985 1986

Family Practice Internship

University of Texas Health Science Center, San Antonio, Texas 1986 1988

Family Practice Residency, Certificate of Completion

Professional Experience:

Metropolitan Health District, City of San Antonio

Health Authority 01/01/11 10/04/12

Metropolitan Health District, City of San Antonio

Interim Medical Director 10/01/11 01/31/13

Metropolitan Health District, City of San Antonio

Interim Health Director 10/01/11 06/01/12

Metropolitan Health District, City of San Antonio

Senior Public Health Physician, City Chest Clinic Medical Director 2005 Present

Metropolitan Health District, City of San Antonio

Senior Public Health Physician 2003 2005

Metropolitan Health District, City of San Antonio

Senior Public Health Physician, STD Clinic Medical Director 1998 2003

Locum Tenens, Pleasanton, Texas

Atascosa Rural Health Center 1997 1998

Locum Tenens, San Antonio Metropolitan Health District

Public Health Consultant 1997 1998

Managed Home Health Care Hospice, Beaumont, Texas

Medical Director 1995 1997

Private Solo Ambulatory Family Practice, Silsbee, Texas 1993 1997

Private Solo General Family Practice, Silsbee, Texas 1992 1993

Metropolitan Health District, City of San Antonio 1990 1992

Public Health Consultant

Locum Tenens 1988 1990

General Ambulatory Family Practice, San Antonio, Texas

Jose Gamboa, M.D. (deceased)

Edgar Galvan, M.D. (deceased), San Antonio, Texas

South Park Medical Care Center, San Antonio, Texas

W.T. Wilde, M.D., Silsbee, Texas

Mulberry Clinic, San Antonio, Texas

Houston Wade, M.D. (deceased)

Leonel Reyes, M.D., San Antonio, Texas

Professional Associations:

Texas Medical Association, Member 1998 present

TMA Council on Health Promotion, Member 2009 2017

TMA Border Health Caucus representing BCMS, Member 2003 present

Bexar County Medical Society, Member 1988 – 1992

1998 present

Chairman Public Health/Patient Advocacy Committee 2007 present

Co chair Public Health/ Patient Advocacy Committee 2004 2007

Medico Legal Committee, Member 2006 present

Emergency Preparedness Committee, Member 2006 present

Other Professional Activities:

National Public Health Leadership Institute Fellow 2011

“Be Our Voice” Project Team Member

RWJF Grantee, Texas Pediatric Society led, advocacy curriculum

training program for healthcare professionals, focusing on pediatric

obesity prevention 2009 2011

Heartland Center, Regional TB Training Center, Faculty 2008 present

TB Expert Clinician Consultant Group 2007 present

National Hispanic Medical Association Leadership Fellowship Program 2001 2002

Community Activities:

American Diabetes Association, Por Tu Familia Committee Chair 2011 present

American Diabetes Association, Diabetes Expo Planning Committee 2007 present

American Diabetes Association Community Leadership Board 2010 present

MALDEF Leadership Program 1991 1992

Other Society Membership:

University Health System, Community

Health Services Advisory Board Chairman 2008 2013

Health Services Advisory Board Member 2004 present

Mexican American Hispanic Physicians Association (MAHPA) 1991 2002

2013

Hardin County Medical Society, Member 1992 1993

Research Activities:

Completed Studies

JJ Nava, Sub I

CDC TB Trials Consortium, Marc Weiner, MD, PI

Study 26 Randomized, open label Phase III clinical trial of ultra short course treatment of latent

TB infection among contacts of active cases, using a 3 month once weekly regimen of isoniazid

and rifapentine, compared to standard 9 month daily therapy with isoniazid. Enrollment of main

populations is completed (more than 8,100 participants have been enrolled and are in follow up).

Enrollment was extended for children and HIV positive populations only, and is now completed.

Those additional subjects are now in follow up.

Study 27 Randomized, double blind, Phase II clinical trial assessing impact on 2 month sputum

conversion rate of substitution of moxifloxacin for ethambutol in standard intensive phase TB

treatment regimen.

Study 28 Randomized, double blind, Phase II clinical trial assessing impact on 2 month sputum

conversion rate of substitution of moxifloxacin for isoniazid in standard intensive phase TB

treatment regimen.

Study 29 Randomized, Phase II clinical trial assessing the antimicrobial activity and safety of

substitution of rifapentine for rifampin in standard intensive phase TB treatment regimen.

JJ Nava, Sub I

SAMHD Immunization Division, Vaccine Clinical Trials, F.A. Guerra, MD, PI

GlaxoSmithKline 2000 2000

HPV epi HPV 106 A multicenter, epidemiology study to evaluate the prevalence of human

papillomavirus (HPV) infections in adolescent and adult females in North America and Brazil.

2000 2003

Cervarix HPV 001 – A double blind, placebo controlled, randomized pilot phase IIB study

of the efficacy of an HPV 16/18 VLP vaccine in the prevention of HPV 16 and/or HPV 18

cervical infection in healthy adolescent and young adult women in North America and Brazil

2003 2005

Twinrix HAB 121 An open, controlled, randomized, comparative, phase IIIb study to evaluate

the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ combined

Hepatitis A and Hepatitis B vaccine [Twinrix® (> 720 EL.U of Hepatitis A antigen and 20 mcg of

hepatitis B surface antigen per mL)) given on an accelerated schedule (0,7, and 21 to 30 days

followed by a booster at month 12), compared to separate vaccinations with GlaxoSmithKline

Biologicals’ monovalent Hepatitis A vaccine (Havrix ®, > 1440 EL.U/1 mL) given on a 0,

12 month schedule and Hepatitis B vaccine (Engerix B®, 20 mcg/1 mL) given on a 0, 1, 2,

12 month schedule) in healthy adults 18 years of age or older.

2003 2005/ 2006

Havrix HAV 220 A Phase IIIb, open, randomized, controlled, multicenter study of the

immunogenicity and safety of GSK Biologicals’ inactivated hepatitis A vaccine(Havrix®) [720

El.U/0.5 mL dose] administered on a 0, 6 month schedule concomitantly with Wyeth Lederle’s

pneumococcal conjugate vaccine (Prevnar™ ) in healthy children 15 months of age

2003 2007/ 2009

Havrix HAV 231 A Phase IIIb, open, randomized, controlled, multicenter study of the

immunogenicity and safety of GlaxoSmithKline Biologicals’ inactivated hepatitis A vaccine

(Havrix®) [720 El.U/0.5 mL dose] administered on a 0, 6 month schedule concomitantly with

Merck an d Company, Inc. measles mumps rubella vaccine (M M R® II) and Merck and

Company, Inc. varicella vaccine (VARIVAX®) to healthy children 15 months of age

2002 2004 / 2007

Cervarix HPV 007 A phase IIb, blinded, multi center, long term follow up study of the efficacy of

candidate HPV 16/18 VLP vaccine in the prevention of HPV 16 and/or HPV 18 cervical infection

in adolescent and young adult women in North America and Brazil vaccinated in primary study

580299/00.

Sanofi Pasteur (Aventis) 2000 2002

Pentacel 494 03 – Safety and Immunogenicity of Pentacel™ When Co administered with Other

Recommended Vaccines at 2, 4, 6 and 15 Months of Age.

2004 2006

Pentacel M5A07 – Immunogenicity Assessment of Pentacel™ (Hybrid

CP20/20/5/3DT mIPV//PRP T) when Given at Different Times from or Concurrently with a

Pneumococcal Conjugate Vaccine

2006 2008

Pentacel M5A10 Comparative Immunogenicity of Different Multivalent Component Pertussis

Vaccine Formulations Based on a 5 component Acellular Pertussis Vaccine in Infants and

Toddlers.

References:

Available on request

Contact this candidate